Response of Breast Cancer Cells to PARP Inhibitors Is Independent of BRCA Status

Response of Breast Cancer Cells to PARP Inhibitors Is Independent of BRCA Status

Poly (ADP-ribose) polymerase inhibitors (PARPi) have proven to be beneficial to patients with metastatic breast cancer with BRCA1/2 (BReast CAncer type 1 and type 2 genes) mutations. However, certain PARPi in pre-clinical studies have been shown to inhibit cell growth and promote the death of breast...

Full description

Bibliographic Details
Main Authors: Man Yee Keung, Yanyuan Wu, Francesca Badar, Jaydutt V. Vadgama
Format: Article
Language:English
Published: MDPI AG 2020-03-01
Series:Journal of Clinical Medicine
Subjects:
PARP inhibitors
Triple-negative breast cancer
BRCA1/2 mutations
HER2-positive breast cancer
Online Access:https://www.mdpi.com/2077-0383/9/4/940

Similar Items

Similar Items